Mirum Pharmaceuticals MIRM 深 滬
等待開盤 03-26 09:30:00 美东时间
90.17
+2.290
+2.61%
華盛通- 最 高91.73
- 今 開88.89
- 成交量 61.45万股
- 最 低 88.35
- 昨 收 87.88
- 總市值 54.41亿
- 52周最高 109.28
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 36.8801
- 委 比 79.55%
- 總股本 6034.16万
- 歷史最高 109.28
- 量 比 0.46
- 振 幅 3.85%
- 歷史最低 6.513
- 每 手 1
- 風險率 18.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：Mirum Pharmaceuticals MSCI（明晟）ESG评级调降至CCC
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:25
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
UPDATE 2-US FDA approves GSK's drug for liver disease-related itching
UPDATE 2-US FDA approves GSK's drug for liver disease-related itching Adds background throughout March 19 (Reuters) - The U.S. Food and Drug Administration approved GSK' s GSK.L drug for severe itching caused by a type of liver disease, the co mpany said on Thursday. The drug, branded Lynavoy, was a
03-19 20:20
BRIEF-Mirum Pharmaceuticals Completes Enrollment In Phase 3 Expand Study Of Livmarli® (Maralixibat) In Additional Rare Cholestatic Liver Diseases
BRIEF-Mirum Pharmaceuticals Completes Enrollment In Phase 3 Expand Study Of Livmarli® (Maralixibat) In Additional Rare Cholestatic Liver Diseases March 16 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O : MIRUM PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 EXPAND STUDY OF LIVMARLI® (MARALIXIBAT) IN A
03-16 20:10
BRIEF-Mirum Pharmaceuticals Provides Azure Clinical Program Update For Brelovitug In Chronic Hepatitis Delta Virus
BRIEF-Mirum Pharmaceuticals Provides Azure Clinical Program Update For Brelovitug In Chronic Hepatitis Delta Virus March 5 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O : MIRUM PHARMACEUTICALS PROVIDES AZURE CLINICAL PROGRAM UPDATE FOR BRELOVITUG IN CHRONIC HEPATITIS DELTA VIRUS MIRUM PHARMACEUTICALS
03-05 21:03
Mirum Completes AZURE-1 Enrollment and AZURE-4 Screening for Brelovitug in Chronic HDV
Mirum Completes AZURE-1 Enrollment and AZURE-4 Screening for Brelovitug in Chronic HDV Mirum Pharmaceuticals said enrollment is complete in its Phase 3 AZURE-1 study and screening is complete in its Phase 3 AZURE-4 study evaluating brelovitug for chronic hepatitis delta virus. The company said these
03-05 21:01
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $125
Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $98 to $125.
02-26 22:35
财报速睇 | Mirum Pharmaceuticals 2025财年Q4营收1.49亿美元，同比增长50.5%；归母净利润亏损0.06亿美元，同比亏损缩窄75.0%
华盛资讯2月26日讯，Mirum Pharmaceuticals公布2025财年Q4业绩，公司Q4营收1.49亿美元，同比增长50.5%，归母净利润亏损0.06亿美元，同比亏损缩窄75.0%。
02-26 07:56
